Pharmaceuticals Machinery Market Forecast Points Higher Toward 2035, Driven by Biologics and Advanced Therapies – News and Statistics

Abstract

According to the latest IndexBox report on the global Pharmaceuticals Machinery market, the market enters 2026 with broader demand fundamentals, more disciplined procurement behavior, and a more regionally diversified supply architecture.

The global pharmaceuticals machinery market is poised for a structural transformation over the 2026-2035 forecast horizon, moving beyond traditional capital equipment sales toward integrated, digitally-enabled solutions. This shift is propelled by the pharmaceutical industry’s pivot toward complex biologics, cell and gene therapies, and personalized medicine, which demand highly flexible, modular, and compliant manufacturing systems. Concurrently, the sustained need for high-volume generic solid dosage and sterile injectable production continues to drive demand for robust, standardized machinery, creating a bifurcated market landscape. Growth will be underpinned by stringent regulatory requirements for data integrity and traceability, the expansion of contract manufacturing, and the global push for regional supply chain resilience. This analysis provides a comprehensive outlook on market dynamics, segment-specific demand drivers, competitive forces, and regional investment patterns shaping the next decade of pharmaceutical production technology.

The baseline scenario for the global pharmaceuticals machinery market from 2026 to 2035 projects steady expansion, supported by fundamental demand for drug manufacturing capacity and technological modernization. The core driver remains the pharmaceutical industry’s ongoing capital expenditure to meet global healthcare needs, including aging populations and the introduction of novel therapies. This scenario assumes continued, though not explosive, growth in traditional small-molecule drug production, coupled with a faster-growing but more specialized segment for advanced therapy medicinal products (ATMPs) and biologics. It incorporates the persistent trend of outsourcing to Contract Development and Manufacturing Organizations (CDMOs), which are significant repeat buyers of standardized and flexible equipment. Geopolitical factors encouraging regionalization of API and finished dose manufacturing, particularly in North America and Europe, will support machinery sales. The outlook is tempered by the high cost and long lifecycle of pharmaceutical equipment, which can delay replacement cycles, and by pricing pressure from Asian OEMs in standardized machinery segments. Overall, the market is expected to evolve from a transactional model to one emphasizing total cost of ownership, digital integration, and lifecycle services.

Demand Drivers and Constraints

Primary Demand Drivers

• Accelerated investment in biologics and cell/gene therapy manufacturing capacity
• Stringent global regulatory mandates for data integrity, serialization, and track-and-trace
• Expansion of the global contract manufacturing (CDMO/CMO) sector requiring flexible, multi-product equipment
• Re-shoring and regionalization of API and critical drug production for supply chain security
• Technological advancement enabling continuous manufacturing and Industry 4.0 integration
• Growing demand for generic solid dosage forms in emerging markets

Potential Growth Constraints

• High capital cost and long replacement cycles for major processing equipment
• Intense price competition, particularly from Asian OEMs in standardized machinery segments
• Complexity and cost of validating new equipment under cGMP and other regulatory frameworks
• Consolidation among large pharmaceutical companies, reducing the number of potential buyers
• Economic volatility and budget constraints affecting capital expenditure decisions in certain regions

Demand Structure by End-Use Industry

Solid Dosage Formulation (estimated share: 32%)

The solid dosage segment, encompassing tablets and capsules, remains the volume backbone of the pharmaceuticals machinery market. Current demand is driven by the massive scale of generic drug production and the ongoing need for oral medications. Through 2035, the segment will not see explosive growth but will evolve significantly. Demand will be sustained by population growth, chronic disease prevalence, and the patent expiry of major drugs. The key change will be the nature of the machinery purchased: a move from standard tablet presses toward high-speed, digitally integrated systems with advanced process analytical technology (PAT) for real-time release. Containment equipment for handling highly potent active pharmaceutical ingredients (HPAPIs) will see above-average growth. Demand-side indicators to watch include generic drug approval rates, CDMO capacity expansions for oral solids, and investment in continuous direct compression lines, which offer efficiency gains for large-volume products. Current trend: Stable core demand with a shift toward high-speed, connected presses and containment solutions.

Major trends: Adoption of continuous manufacturing lines over traditional batch processing, Integration of real-time monitoring and PAT for quality-by-design (QbD), Increased demand for containment solutions for potent compound handling, and Rise of modular and flexible systems to allow quick product changeovers in multi-product facilities.

Representative participants: IMA Group (IMA Active), Fette Compacting (part of the LMT Group), Korsch AG, Romaco Group, ACG, and Elizabeth Hata International.

Sterile Injectables & Biologics Manufacturing (estimated share: 28%)

This sector covers machinery for producing parenteral drugs, including vial/syringe fillers, lyophilizers (freeze dryers), and isolator/restricted access barrier systems (RABS). Current demand is elevated due to post-pandemic vaccine capacity build-out and the robust pipeline of biologic drugs, which are predominantly injectable. Through 2035, this will be the highest-growth segment, driven by the clinical and commercial success of monoclonal antibodies, recombinant proteins, and other complex molecules. The demand story is mechanism-based: biologics require aseptic processing and often lyophilization for stability, mandating specialized, high-value equipment. Demand-side indicators include the number of biologic drugs in late-stage clinical trials, investments in new fill-finish facilities by large biopharma and CDMOs, and regulatory trends favoring closed-system processing to reduce contamination risk. The shift toward pre-filled syringes and dual-chamber systems will also spur new packaging machinery requirements. Current trend: High-growth segment driven by biologics pipeline and vaccine production needs.

Major trends: Accelerated adoption of closed, automated systems (isolators) over cleanrooms, Growth in lyophilizer capacity and capability for high-value biologics, Increasing line speeds and integration for high-volume vaccine production, and Rise of flexible, small-batch systems for clinical and personalized therapy manufacturing.

Representative participants: Syntegon Technology GmbH, Bausch+Ströbel (IMA), IMA Life, Optima Pharma (Optima Group), Groninger & Co. GmbH, and SP Scientific.

API Synthesis & High-Potency Manufacturing (estimated share: 18%)

This segment involves equipment for the production of Active Pharmaceutical Ingredients (APIs), including reactors, centrifuges, dryers, and purification systems. The current market is characterized by a push to modernize aging assets and build new, geographically diversified capacity outside of traditional Asian hubs, driven by supply chain security concerns. Through 2035, demand will be supported by the regionalization trend in North America and Europe, as well as the growing complexity of APIs for targeted therapies, which often require specialized synthesis and stringent containment. The mechanism is direct: building a new API plant requires a full suite of primary processing equipment. Key demand indicators include announced investments in new API production facilities, particularly for critical medicines and oncology drugs, regulatory scrutiny of overseas API suppliers, and the growth of the HPAPI market. Technology trends favoring continuous flow chemistry will also create demand for new, modular reactor systems. Current trend: Modernization and regionalization driving demand for reactors, dryers, and containment.

Major trends: Investment in continuous manufacturing technologies for API production, Heightened focus on containment solutions for high-potency compound handling, Adoption of single-use bioreactors and components in upstream bioprocessing, and Modernization of legacy chemical API plants with digital control and monitoring systems.

Representative participants: GEA Group, Siemens AG (Process Automation), Cytiva, Thermo Fisher Scientific (Process Solutions), Pall Corporation, and Sulzer Ltd.

Primary & Secondary Packaging (estimated share: 15%)

This sector includes blister packers, cartoners, labelers, serialization and aggregation equipment. Current demand is heavily influenced by the need to comply with global serialization regulations (e.g., DSCSA in the US, FMD in the EU), which has driven a major investment cycle. Through 2035, while the initial serialization push will moderate, demand will be sustained by the need for line upgrades, higher automation to reduce labor costs, and integration with enterprise systems for track-and-trace. The demand mechanism is twofold: regulatory compliance is non-negotiable, and operational efficiency gains from automated packaging lines provide a clear ROI. Key indicators include the rate of line modernization projects, expansion of packaging capacity in high-growth regions, and the adoption of smart packaging technologies that interact with digital health ecosystems. Sustainability pressures will also drive demand for machinery capable of handling recycled materials and reducing packaging waste. Current trend: Automation and serialization compliance as primary investment drivers.

Major trends: Integration of advanced vision inspection and reject systems for quality assurance, Rise of robotic pick-and-place and palletizing systems for flexible operations, Growing demand for modular packaging lines that can handle multiple pack formats, and Increased focus on sustainability, driving machinery for lightweight and recyclable packaging.

Representative participants: Robert Bosch GmbH (Packaging Technology), Coesia S.p.A. (MG2, Norden), Marchesini Group, Uhlmann Group, Körber AG (Business Area Pharma), and IMA Group (IMA Packaging).

Cleaning, Sterilization & Utilities Support (estimated share: 7%)

This segment covers washers, sterilizers (autoclaves), clean-in-place (CIP) systems, and water-for-injection (WFI) generation equipment. It is a critical, non-discretionary part of pharmaceutical manufacturing where failure is not an option. Current demand is steady, driven by facility expansions, regulatory emphasis on contamination control, and the need to replace aging equipment. Through 2035, growth will be linked to the overall expansion of manufacturing capacity, particularly in biologics and sterile manufacturing, where cleaning and sterilization standards are most stringent. The demand mechanism is compliance-driven and efficiency-focused: regulators mandate validated cleaning processes, and manufacturers seek automated CIP/SIP (sterilize-in-place) systems to reduce downtime, labor, and human error. Demand indicators include capital budgets for facility upgrades, regulatory inspection trends focusing on cross-contamination, and the adoption of single-use technologies, which paradoxically reduce some cleaning needs but increase demand for supporting sterilization of components. Current trend: Critical for compliance and efficiency, with growth in automated clean-in-place (CIP) systems.

Major trends: Shift from manual cleaning to automated, validated CIP/SIP systems, Increasing use of vaporized hydrogen peroxide (VHP) and other advanced sterilization methods, Integration of sterilization equipment with facility management systems for data logging, and Demand for more energy- and water-efficient cleaning systems.

Representative participants: Getinge AB, Steris plc, Fedegari Autoclavi S.p.A, Synthesys Group, Tofflon Science and Technology Group, and Sotera Health.

Key Market Participants

Regional Dynamics

Asia-Pacific (estimated share: 38%)

Asia-Pacific remains the largest and fastest-growing market, driven by massive generic drug production in India, China’s evolving biopharma sector, and significant capacity expansions across Southeast Asia. The region is both a major consumer of high-end machinery from Western OEMs and a source of cost-competitive standardized equipment. Government initiatives like ‘Make in India’ and China’s focus on innovative drug development are fueling sustained investment. Direction: Dominant and growing.

North America (estimated share: 28%)

North America’s market is characterized by high-value investments in advanced therapy and biologics manufacturing, as well as modernization of existing facilities for compliance and efficiency. The US push for supply chain resilience is driving new API and finished dose manufacturing projects. Demand is skewed toward high-tech, automated, and digitally integrated systems, with a strong aftermarket for services and upgrades. Direction: Steady growth with premium focus.

Europe (estimated share: 24%)

Europe is a mature market with a strong base of innovative pharmaceutical companies and CDMOs. Growth is driven by the need to modernize aging assets for digital integration and sustainability, alongside investments in cell/gene therapy hubs. Stringent environmental regulations are accelerating the replacement of older, less efficient equipment. Western Europe remains a key market for premium machinery, while Eastern Europe sees growth as a manufacturing location. Direction: Mature but modernizing.

Latin America (estimated share: 6%)

The Latin American market is fragmented, with growth concentrated in Brazil and Mexico. Demand is primarily for cost-effective machinery to serve local and regional generic drug markets, with some investment by multinationals for local production. Economic volatility can constrain large capital projects, but the essential nature of pharmaceuticals provides a stable baseline for equipment needs. Direction: Moderate, localized growth.

Middle East & Africa (estimated share: 4%)

This region represents a smaller but strategically emerging market. Growth is driven by government initiatives to build local pharmaceutical manufacturing capacity for essential medicines and vaccines, reducing import dependency. The Gulf Cooperation Council (GCC) countries are investing in high-tech facilities, while other parts of the region focus on basic production. The market is price-sensitive but offers long-term potential. Direction: Emerging from a low base.

Market Outlook (2026-2035)

In the baseline scenario, IndexBox estimates a 5.2% compound annual growth rate for the global pharmaceuticals machinery market over 2026-2035, bringing the market index to roughly 165 by 2035 (2025=100).

Note: indexed curves are used to compare medium-term scenario trajectories when full absolute volumes are not publicly disclosed.

For full methodological details and benchmark tables, see the latest IndexBox Pharmaceuticals Machinery market report.